MarketPulse
R

$RLMD

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada Therapeutics to Unveil Q4 2025 Results Amid $160M Funding Boost

Relmada Therapeutics to report Q4 2025 results March 19, 2026, following $160M oversubscribed fundraise and Leerink Partners conference presentation.
RLMDclinical-stage biotechprivate placement
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials